{"id":"isovaleryl-diethylamide","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":["NCT04774068","NCT05901545","NCT00466817","NCT01590732","NCT00031486","NCT01897012","NCT03699254","NCT05245006","NCT01638533","NCT03311828","NCT00031434","NCT03534180","NCT04333537","NCT03495427","NCT01056107","NCT04820049","NCT06621017","NCT03432741","NCT03121989","NCT03278782","NCT05468619"],"aliases":[],"patents":[],"pricing":[],"allNames":"valyl","offLabel":[],"synonyms":["isovaleryl diethylamide","N,N-Diethylisovaleramide","valimyl","valyl","xalyl"],"timeline":[],"approvals":[],"brandName":"Valyl","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and Valyl is a key that fits into one of those locks. When it binds, it can either turn the lock on or off, depending on the type of lock and the key's shape. This interaction can affect how cells behave and communicate with each other, potentially leading to changes in the body's response to certain stimuli.","oneSentence":"Valyl is thought to work by interacting with a specific molecular target, although the exact mechanism is currently unknown.","technicalDetail":"Valyl's mechanism of action is believed to involve the modulation of a specific molecular target, although the precise details of this interaction are currently unknown and require further investigation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3762","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=isovaleryl diethylamide","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:11:41.217152","biosimilars":[],"competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"isovaleryl diethylamide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04774068","phase":"Phase 1","title":"A Phase I Study of Romidepsin in Combination With Parsaclisib in Relapsed and Refractory T-Cell Lymphomas","status":"COMPLETED","sponsor":"Walter Hanel","isPivotal":false,"enrollment":5,"indication":"Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","completionDate":"2024-10-27"},{"nctId":"NCT05901545","phase":"Phase 1","title":"Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer","status":"RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","isPivotal":false,"enrollment":30,"indication":"Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma","completionDate":"2029-11-30"},{"nctId":"NCT00466817","phase":"Phase 3","title":"A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":true,"enrollment":109,"indication":"Cytomegalovirus Infection","completionDate":"2013-06"},{"nctId":"NCT01590732","phase":"Phase 1","title":"Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":22,"indication":"Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma","completionDate":"2018-05-02"},{"nctId":"NCT00031486","phase":"Phase 3","title":"A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":true,"enrollment":91,"indication":"Encephalitis","completionDate":"2011-02"},{"nctId":"NCT01897012","phase":"Phase 1","title":"A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":26,"indication":"MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma","completionDate":"2018-11-30"},{"nctId":"NCT03699254","phase":"Phase 3","title":"Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis to Prevent Cytomegalovirus Disease in Lung Transplant Recipients (CYTOCOR STUDY): An Open-l","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","isPivotal":true,"enrollment":150,"indication":"Transplantation Infection, Cytomegalovirus Infections","completionDate":"2023-05-29"},{"nctId":"NCT05245006","phase":"Phase 1","title":"A First-in-Human, Pilot PET Imaging Study of 89Zr-DFO-YS5, an immunoPET Agent for Detecting CD46 Positive Malignancy in Men With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Robert Flavell, MD, PhD","isPivotal":false,"enrollment":30,"indication":"Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","completionDate":"2027-07-31"},{"nctId":"NCT01638533","phase":"Phase 1","title":"A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":37,"indication":"Glioma, Hematopoietic and Lymphoid Cell Neoplasm","completionDate":"2020-09-01"},{"nctId":"NCT03311828","phase":"Phase 1","title":"A Pilot/Feasibility Trial of 64Cu-DOTA-Daratumumab Positron Emission Tomography in Patients With Newly Diagnosed or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","isPivotal":false,"enrollment":12,"indication":"Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma","completionDate":"2023-06-05"},{"nctId":"NCT00031434","phase":"Phase 1","title":"A Phase I/II Pharmacokinetic and Pharmacodynamic Evaluation of Oral Valganciclovir in Neonates With Symptomatic Congenital Cytomegalovirus (CMV) Infection (CASG 109)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":24,"indication":"Cytomegalovirus Infections","completionDate":"2007-07"},{"nctId":"NCT03534180","phase":"Phase 2","title":"A Phase 2 Study of Venetoclax and Romidepsin With Safety Lead-In for Treatment of Relapsed/Refractory Mature T-Cell Lymphomas","status":"COMPLETED","sponsor":"City of Hope Medical Center","isPivotal":false,"enrollment":12,"indication":"Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","completionDate":"2023-07-26"},{"nctId":"NCT04333537","phase":"Phase 2","title":"Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer","status":"RECRUITING","sponsor":"NRG Oncology","isPivotal":true,"enrollment":686,"indication":"Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma","completionDate":"2031-04-27"},{"nctId":"NCT03495427","phase":"Phase 2","title":"The Utility of PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men With High GC Decipher® Test Scores: A Sub-aim of the VANDAAM Study (MCC #18523)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","isPivotal":true,"enrollment":60,"indication":"Prostate Cancer, Recurrent Prostate Cancer","completionDate":"2029-05"},{"nctId":"NCT01056107","phase":"Phase 1","title":"Effect of ROSE-010 on Gastrointestinal Motor Functions in Female Patients With Constipation Predominant Irritable Bowel Syndrome (C-IBS)","status":"COMPLETED","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":52,"indication":"Irritable Bowel Syndrome Constipation Predominant","completionDate":"2011-12"},{"nctId":"NCT04820049","phase":"Phase 1","title":"F573 for Injection Phase Ia Clinical Trial.","status":"COMPLETED","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","isPivotal":false,"enrollment":100,"indication":"Tolerance, Pharmacokinetic","completionDate":"2022-11-06"},{"nctId":"NCT06621017","phase":"Phase 2","title":"A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Daily Administrations of the GLP-1 Analogue ROSE-010 on Appetite and Food ","status":"COMPLETED","sponsor":"Rose Pharma Inc","isPivotal":false,"enrollment":40,"indication":"Obesity; Overweight","completionDate":"2025-02-27"},{"nctId":"NCT03432741","phase":"Phase 1","title":"Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET","status":"TERMINATED","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":17,"indication":"Breast Adenocarcinoma, Metastatic Breast Carcinoma","completionDate":"2022-10-03"},{"nctId":"NCT03121989","phase":"Phase 1","title":"Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy","status":"WITHDRAWN","sponsor":"Sunnybrook Health Sciences Centre","isPivotal":false,"enrollment":0,"indication":"Breast Cancer","completionDate":"2023-03-23"},{"nctId":"NCT03278782","phase":"Phase 1","title":"A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":39,"indication":"Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma","completionDate":"2027-07-31"},{"nctId":"NCT05468619","phase":"Phase 1","title":"A Phase I Adaptive, Multiple Dose Pharmacokinetic and Safety Assessment of Valacyclovir in Infants at Risk of Acquiring Neonatal Herpes Simplex Virus Disease","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":17,"indication":"Herpes Simplex","completionDate":"2025-07-15"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"A9RAN1A34P","CHEBI":"CHEBI:134787","chemblId":"CHEMBL516258","pubchemSID":"90976","PUBCHEM_CID":"68290"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Valyl, also known as isovaleryl diethylamide, is a small molecule compound with unknown drug class and target. Its development and current ownership are not publicly disclosed. The compound's pharmacological properties, including its half-life, bioavailability, and approved indications, are also unknown. As a result, its commercial status and key safety considerations cannot be determined. Further research is needed to understand the compound's potential therapeutic applications and risks.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}